Aventis Launches Preservative-Free Vaccine for Tetanus and Diphtheria We are pleased to announce the availability of DECAVAC™ (Tetanus and Diphtheria Toxoids Adsorbed For Adult Use), the company’s recently licensed preservative-free tetanus and diphtheria (Td) vaccine. DECAVAC vaccine is formulated without preservatives; only a trace amount of thimerosal (≤0.3 µg mercury per dose) remains from the manufacturing process. As the nation’s major supplier of Td vaccine, Aventis Pasteur, the vaccines business of the sanofi-aventis Group, is dedicated to maintaining public confidence in vaccines and ensuring a smooth transition for customers from the traditional Td vaccine to the new preservative-free DECAVAC vaccine. Health-care providers can place orders for DECAVAC vaccine on-line at www.vaccineshoppe.com or by calling 1-800-VACCINE (1-800-822-2463). DECAVAC vaccine contains the same tetanus and diphtheria components utilized in Aventis Pasteur’s previous Td vaccine, but now it is supplied preservative-free in a single-dose, prefilled syringe. DECAVAC vaccine is indicated for use as a routine booster every 10 years throughout life for persons seven years of age or older who have received a primary series of tetanus- and diphtheria-containing vaccine. It is also used for wound care in persons who have not received a tetanus toxoid-containing preparation within the preceding five years. While 80% of Americans aged 12 to 19 have protective levels of antibodies to fight these two diseases, just 47% of adults over 20 years of age are protected.1 Therefore, it is important to be aware of the vaccination status for all of your adolescent and adult patients and make sure they get the tetanus-diphtheria booster immunization every 10 years to stay protected. Aventis Pasteur decided several years ago to pursue preservative-free formulations. The launch of DECAVAC vaccine is an example of this commitment. The preservative thimerosal is used in the production process for many vaccines. There are trace amounts of thimerosal left over from the production process that cannot be removed, but these amounts are so small that the Food and Drug Administration, US Centers for Disease Control and Prevention and the Institute of Medicine consider DECAVAC vaccine to be preservative-free. Safety Information There are risks associated with all vaccines, including DECAVAC™ (Tetanus and Diphtheria Toxoids Adsorbed For Adult Use). The most common local adverse reactions associated with Td may include erythema (redness), tenderness, and swelling at the injection site. Common systemic reactions may include headache, malaise, and temperature elevations. Additional adverse reactions reported between 1998-2003 during post-approval use of Td vaccine include local reactions at injection site (swelling, redness, warmth, cellulitis), myalgia, arthralgia, muscle stiffness, nausea, vomiting, paraesthesia, dizziness, convulsions, and rash. Arthus-type hypersensitivity reactions, characterized by severe local reactions (generally starting 2.8 hours after an injection), may follow receipt of tetanus toxoid. Persistent nodules at the site of injection have been reported following the use of adsorbed products. More serious adverse reactions may occur but are rare. DECAVAC vaccine is contraindicated in patients with hypersensitivity to any component of the vaccine. As with any vaccine, vaccination with DECAVAC vaccine may not protect 100% of individuals. For full prescribing information, see the DECAVAC vaccine package insert at www.us.aventispasteur.com. To unsubscribe from TdUpdate, respond to this e-mail with the word "unsubscribe" in the subject line. Anyone interested in subscribing to TdUpdate may do so by e-mailing firstname.lastname@example.org with the word "subscribe" in the subject line. We also value your input; comments and suggestions can be addressed to email@example.com or submitted by replying to this e-mail. Aventis Pasteur, Inc., Discovery Drive, Swiftwater, PA 18370. 1 McQuillan GM, Kruszon-Moran D, Deforest A, Chu Sy, and Wharton M, Serologic Immunity to Diphtheria and Tetanus in the United States, Annals of Internal Medicine, May 7, 2002, vol 136, p. 660.